164 related articles for article (PubMed ID: 10569202)
41. Human CD8 and CD4 T cell epitopes of epithelial cancer antigens.
Sato N; Nabeta Y; Kondo H; Sahara H; Hirohashi Y; Kashiwagi K; Kanaseki T; Sato Y; Rong S; Hirai I; Kamiguchi K; Tamura Y; Matsuura A; Takahashi S; Torigoe T; Ikeda H
Cancer Chemother Pharmacol; 2000; 46 Suppl():S86-90. PubMed ID: 10950155
[TBL] [Abstract][Full Text] [Related]
42. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
Engelhard VH; Bullock TN; Colella TA; Mullins DW
Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
[TBL] [Abstract][Full Text] [Related]
43. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
[TBL] [Abstract][Full Text] [Related]
44. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells.
Wang RF; Wang X; Rosenberg SA
J Exp Med; 1999 May; 189(10):1659-68. PubMed ID: 10330445
[TBL] [Abstract][Full Text] [Related]
45. A theoretical approach for T-lymphocyte monitoring of autologous cancer vaccine therapy using autologous HLA-class I and HLA-class II constructs.
Schiltz P; Dillman R
Cancer Biother Radiopharm; 2004 Aug; 19(4):405-10. PubMed ID: 15453955
[TBL] [Abstract][Full Text] [Related]
46. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.
Saito T; Wada H; Yamasaki M; Miyata H; Nishikawa H; Sato E; Kageyama S; Shiku H; Mori M; Doki Y
Vaccine; 2014 Oct; 32(45):5901-7. PubMed ID: 25218300
[TBL] [Abstract][Full Text] [Related]
47. Tumor-specific shared antigenic peptides recognized by human T cells.
Van Der Bruggen P; Zhang Y; Chaux P; Stroobant V; Panichelli C; Schultz ES; Chapiro J; Van Den Eynde BJ; Brasseur F; Boon T
Immunol Rev; 2002 Oct; 188():51-64. PubMed ID: 12445281
[TBL] [Abstract][Full Text] [Related]
48. MHC Class II-Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine Design.
Zeng G
J Immunother (1991); 2001 May; 24(3):195-204. PubMed ID: 11395634
[TBL] [Abstract][Full Text] [Related]
49. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
Röhn TA; Reitz A; Paschen A; Nguyen XD; Schadendorf D; Vogt AB; Kropshofer H
Cancer Res; 2005 Nov; 65(21):10068-78. PubMed ID: 16267033
[TBL] [Abstract][Full Text] [Related]
50. Human tumor antigens recognized by T lymphocytes: implications for cancer therapy.
Wang RF; Rosenberg SA
J Leukoc Biol; 1996 Sep; 60(3):296-309. PubMed ID: 8830785
[TBL] [Abstract][Full Text] [Related]
51. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
[TBL] [Abstract][Full Text] [Related]
52. Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide.
Ladányi A; Nishimura MI; Rosenberg SA; Yang JC
J Immunother; 2000 Jan; 23(1):36-47. PubMed ID: 10687136
[TBL] [Abstract][Full Text] [Related]
53. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
[TBL] [Abstract][Full Text] [Related]
54. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A.
Markiewicz MA; Fallarino F; Ashikari A; Gajewski TF
Int Immunol; 2001 May; 13(5):625-32. PubMed ID: 11312250
[TBL] [Abstract][Full Text] [Related]
55. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
[TBL] [Abstract][Full Text] [Related]
56. An autologous oral DNA vaccine protects against murine melanoma.
Xiang R; Lode HN; Chao TH; Ruehlmann JM; Dolman CS; Rodriguez F; Whitton JL; Overwijk WW; Restifo NP; Reisfeld RA
Proc Natl Acad Sci U S A; 2000 May; 97(10):5492-7. PubMed ID: 10779556
[TBL] [Abstract][Full Text] [Related]
57. Presentation of endogenous tumor antigens to CD4+ T lymphocytes by murine melanoma cells transfected with major histocompatibility complex class II genes.
Chen PW; Ullrich SE; Ananthaswamy HN
J Leukoc Biol; 1994 Oct; 56(4):469-74. PubMed ID: 7930943
[TBL] [Abstract][Full Text] [Related]
58. Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.
Donia M; Andersen R; Kjeldsen JW; Fagone P; Munir S; Nicoletti F; Andersen MH; Thor Straten P; Svane IM
Cancer Res; 2015 Sep; 75(18):3747-59. PubMed ID: 26183926
[TBL] [Abstract][Full Text] [Related]
59. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
[TBL] [Abstract][Full Text] [Related]
60. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
